Cargando…
Palliative chemotherapy or best supportive care? A prospective study explaining patients' treatment preference and choice
In palliative cancer treatment, the choice between palliative chemotherapy and best supportive care may be difficult. In the decision-making process, giving information as well as patients' values and preferences become important issues. Patients, however, may have a treatment preference before...
Autores principales: | , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2003
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2395270/ https://www.ncbi.nlm.nih.gov/pubmed/14676798 http://dx.doi.org/10.1038/sj.bjc.6601445 |
_version_ | 1782155467775016960 |
---|---|
author | Koedoot, C G de Haan, R J Stiggelbout, A M Stalmeier, P F M de Graeff, A Bakker, P J M de Haes, J C J M |
author_facet | Koedoot, C G de Haan, R J Stiggelbout, A M Stalmeier, P F M de Graeff, A Bakker, P J M de Haes, J C J M |
author_sort | Koedoot, C G |
collection | PubMed |
description | In palliative cancer treatment, the choice between palliative chemotherapy and best supportive care may be difficult. In the decision-making process, giving information as well as patients' values and preferences become important issues. Patients, however, may have a treatment preference before they even meet their medical oncologist. An insight into the patient's decision-making process can support clinicians having to inform their patients. Patients (n=207) with metastatic cancer, aged 18 years or older, able to speak Dutch, for whom palliative chemotherapy was a treatment option, were eligible for the study. We assessed the following before they consulted their medical oncologist: (1) socio-demographic characteristics, (2) disease-related variables, (3) quality-of-life indices, (4) attitudes and (5) preferences for treatment, information and participation in decision-making. The actual treatment decision, assessed after it had been made, was the main study outcome. Of 207 eligible patients, 140 patients (68%) participated in the study. At baseline, 68% preferred to undergo chemotherapy rather than wait watchfully. Eventually, 78% chose chemotherapy. Treatment preference (odds ratio (OR)=10.3, confidence interval (CI) 2.8–38.0) and a deferring style of decision-making (OR=4.9, CI 1.4–17.2) best predicted the actual treatment choice. Treatment preference (total explained variance=38.2%) was predicted, in turn, by patients' striving for length of life (29.5%), less striving for quality of life (6.1%) and experienced control over the cause of disease (2.6%). Patients' actual treatment choice was most strongly predicted by their preconsultation treatment preference. Since treatment preference is positively explained by striving for length of life, and negatively by striving for quality of life, it is questionable whether the purpose of palliative treatment is made clear. This, paradoxically, emphasises the need for further attention to the process of information giving and shared decision-making. |
format | Text |
id | pubmed-2395270 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2003 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-23952702009-09-10 Palliative chemotherapy or best supportive care? A prospective study explaining patients' treatment preference and choice Koedoot, C G de Haan, R J Stiggelbout, A M Stalmeier, P F M de Graeff, A Bakker, P J M de Haes, J C J M Br J Cancer Clinical In palliative cancer treatment, the choice between palliative chemotherapy and best supportive care may be difficult. In the decision-making process, giving information as well as patients' values and preferences become important issues. Patients, however, may have a treatment preference before they even meet their medical oncologist. An insight into the patient's decision-making process can support clinicians having to inform their patients. Patients (n=207) with metastatic cancer, aged 18 years or older, able to speak Dutch, for whom palliative chemotherapy was a treatment option, were eligible for the study. We assessed the following before they consulted their medical oncologist: (1) socio-demographic characteristics, (2) disease-related variables, (3) quality-of-life indices, (4) attitudes and (5) preferences for treatment, information and participation in decision-making. The actual treatment decision, assessed after it had been made, was the main study outcome. Of 207 eligible patients, 140 patients (68%) participated in the study. At baseline, 68% preferred to undergo chemotherapy rather than wait watchfully. Eventually, 78% chose chemotherapy. Treatment preference (odds ratio (OR)=10.3, confidence interval (CI) 2.8–38.0) and a deferring style of decision-making (OR=4.9, CI 1.4–17.2) best predicted the actual treatment choice. Treatment preference (total explained variance=38.2%) was predicted, in turn, by patients' striving for length of life (29.5%), less striving for quality of life (6.1%) and experienced control over the cause of disease (2.6%). Patients' actual treatment choice was most strongly predicted by their preconsultation treatment preference. Since treatment preference is positively explained by striving for length of life, and negatively by striving for quality of life, it is questionable whether the purpose of palliative treatment is made clear. This, paradoxically, emphasises the need for further attention to the process of information giving and shared decision-making. Nature Publishing Group 2003-12-15 2003-12-09 /pmc/articles/PMC2395270/ /pubmed/14676798 http://dx.doi.org/10.1038/sj.bjc.6601445 Text en Copyright © 2003 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Clinical Koedoot, C G de Haan, R J Stiggelbout, A M Stalmeier, P F M de Graeff, A Bakker, P J M de Haes, J C J M Palliative chemotherapy or best supportive care? A prospective study explaining patients' treatment preference and choice |
title | Palliative chemotherapy or best supportive care? A prospective study explaining patients' treatment preference and choice |
title_full | Palliative chemotherapy or best supportive care? A prospective study explaining patients' treatment preference and choice |
title_fullStr | Palliative chemotherapy or best supportive care? A prospective study explaining patients' treatment preference and choice |
title_full_unstemmed | Palliative chemotherapy or best supportive care? A prospective study explaining patients' treatment preference and choice |
title_short | Palliative chemotherapy or best supportive care? A prospective study explaining patients' treatment preference and choice |
title_sort | palliative chemotherapy or best supportive care? a prospective study explaining patients' treatment preference and choice |
topic | Clinical |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2395270/ https://www.ncbi.nlm.nih.gov/pubmed/14676798 http://dx.doi.org/10.1038/sj.bjc.6601445 |
work_keys_str_mv | AT koedootcg palliativechemotherapyorbestsupportivecareaprospectivestudyexplainingpatientstreatmentpreferenceandchoice AT dehaanrj palliativechemotherapyorbestsupportivecareaprospectivestudyexplainingpatientstreatmentpreferenceandchoice AT stiggelboutam palliativechemotherapyorbestsupportivecareaprospectivestudyexplainingpatientstreatmentpreferenceandchoice AT stalmeierpfm palliativechemotherapyorbestsupportivecareaprospectivestudyexplainingpatientstreatmentpreferenceandchoice AT degraeffa palliativechemotherapyorbestsupportivecareaprospectivestudyexplainingpatientstreatmentpreferenceandchoice AT bakkerpjm palliativechemotherapyorbestsupportivecareaprospectivestudyexplainingpatientstreatmentpreferenceandchoice AT dehaesjcjm palliativechemotherapyorbestsupportivecareaprospectivestudyexplainingpatientstreatmentpreferenceandchoice |